NASDAQ · APGE
Healthcare · Biotechnology
$134.57
Down-$0.02 (-0.01%)
Updated Aug 19, 2026, 8:11 AM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
APGE does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning APGE.
APGE research
Company profile and research snapshot.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Truist Securities | Hold | — |
| Aug 12, 2026 | BTIG | Neutral | — |
| Jun 24, 2026 | Stifel | Hold | — |
| Jun 24, 2026 | TD Cowen | Hold | — |
| Jun 24, 2026 | Mizuho | Neutral | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Truist Securities analyst Danielle Brill maintains Apogee Therapeutics (NASDAQ:APGE) with a Hold and raises the price target from $81 to $135.
Benzinga · Aug 12, 2026
BTIG analyst Julian Harrison downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral.
Benzinga · Aug 10, 2026
Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share
Yahoo · Aug 7, 2026
In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning APGE.
